Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

12.75 -1.85

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.68

Massimo

12.82

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

140.9

56.597

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

537M

2.4B

Apertura precedente

14.6

Chiusura precedente

12.75

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 set 2026, 12:41 UTC

News

Solana is trading higher as investor interest in cryptocurrency strengthens, aided by positive momentum from Ethereum and Pepeto's successful presale raising $10.96 million.

12 set 2026, 00:06 UTC

Macro News
Macro Event
News

Bitcoin trades higher, nearing $79,000, as the market rebounds from $388 million in liquidations amid inflation concerns and declining crude oil prices.

12 set 2026, 00:01 UTC

News

Kroger Co reported mixed second-quarter results, with shares lower in after-market trading. EPS guidance for the fiscal year is set between $5.10 and $5.30.

12 set 2026, 00:01 UTC

Social Media
News

Scholar Rock Holding Corp shares rose in after-market trading following FDA approval of ISEMBYLD for spinal muscular atrophy, with commercial supply set to begin shortly.

12 set 2026, 00:01 UTC

News

Nasdaq Inc announced a $100 million investment in Payward to develop blockchain-based equities, launching Nasdaq Equity Tokens in 2027. Shares traded higher in after-market hours.

12 set 2026, 00:01 UTC

News
Social Media

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

12 set 2026, 00:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion common stock offering announcement, raising investor concerns over potential dilution.

11 set 2026, 23:56 UTC

News

Ionis Pharmaceuticals received FDA approval for ZANVASTRO. Shares are higher in after-market trading, reflecting positive sentiment despite a setback in a partnered trial.

11 set 2026, 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

11 set 2026, 23:26 UTC

News

Bentley Systems declared a quarterly dividend of $0.07 per share, scheduled for September 29, 2026, with shares trading higher in after-market hours.

11 set 2026, 23:16 UTC

News

Carriage Services Inc shares higher in after-hours trading, following a Friday close. Analysts set an average price target of $51.00, indicating potential upside.

11 set 2026, 23:06 UTC

Macro Event
News

Ethereum is higher in Friday's session, recovering after four days of declines. The asset remains above its 20-day moving average amid rising inflation pressures.

11 set 2026, 23:06 UTC

Macro Event
News

Ethereum is rising during Friday's session, supported by recent inflation data and fluctuating crude oil prices. The asset remains above its 20-day moving average.

11 set 2026, 23:01 UTC

Social Media
News

Oracle Corp's after-market shares declined following a $700 million expansion of its restructuring plan, raising total costs to $2.8 billion amid financial pressures.

11 set 2026, 23:01 UTC

News

Nasdaq Inc. shares rose in after-market trading following a $100 million investment in Payward to develop Nasdaq Equity Tokens, set to launch in 2027.

11 set 2026, 23:01 UTC

Social Media
News

Corning Inc shares fell in after-market trading following a $2 billion stock offering announcement, raising investor concerns about potential dilution.

11 set 2026, 22:51 UTC

News
Social Media

Scholar Rock Holding Corp gains after FDA approves ISEMBYLD for spinal muscular atrophy, with a U.S. launch set to begin shortly.

11 set 2026, 22:01 UTC

News

Estée Lauder Companies secured a legal win against Walmart over counterfeit products, but shares are trading lower in after-market hours amid ongoing retail sector concerns.

11 set 2026, 21:31 UTC

News

Warner Bros Discovery Inc. shares are higher in after-market hours following reports of Paramount's settlement talks with state attorneys general over its acquisition proposal.

11 set 2026, 20:51 UTC

News

Ralph Lauren Corp's Board declared a quarterly dividend of $1.00 per share, and shares are trading higher in after-market hours.

11 set 2026, 20:09 UTC

News

1-800-Flowers.Com Inc shares are lower after reporting Q2 revenue of $293.1 million and a non-GAAP loss of $0.80 per share.

11 set 2026, 20:09 UTC

News

Century Communities plans to open Grand Oaks of Callaway in Florida on September 26, featuring homes starting from the upper $200s. Shares are gaining.

11 set 2026, 20:09 UTC

News

Columbia Sportswear appoints Peter Rauch as President of Mountain Hardwear, effective September 28. Shares are higher today, despite pulling back from an earlier session high.

11 set 2026, 20:09 UTC

News

Clear Secure shares are lower after DA Davidson analyst Wyatt Swanson cut the price target to $45.00 from $55.00 while maintaining a Neutral rating.

11 set 2026, 20:09 UTC

News

Carvana Co's shares are lower today, continuing a downward trend amid institutional investment activity and persistent inflation pressures indicated by recent CPI data.

11 set 2026, 20:09 UTC

News

Ultragenyx Pharmaceutical shares are lower as Bronstein, Gewirtz & Grossman, LLC, initiates an investigation following disappointing Phase 3 study results for apazunersen.

11 set 2026, 20:09 UTC

News
Social Media
Correlated Moves

Snowflake Inc. shares are declining amid insider selling by director Benoit Dageville, who sold 50,000 shares at $335.72 on September 9.

11 set 2026, 20:09 UTC

News
Social Media

Advanced Micro Devices shares are higher today following positive growth projections for its server and data center businesses, potentially exceeding $65 billion by Q4 2026.

11 set 2026, 20:09 UTC

News

Intercontinental Exchange sponsors the 9/11 Day of Service initiative. Shares are advancing during Friday's trading, reflecting positive momentum since Thursday's close.

11 set 2026, 20:09 UTC

News
Social Media

Marvell Technology reports fiscal Q2 revenue of $2.73 billion, exceeding estimates. Shares are higher amid strong demand for AI networking and advanced technologies.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Consenso sulla valutazione

By TipRanks

Da acquistare moderatamente

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat